Thursday, October 15, 2026

Copper Futures Over 2% Down In The Last 5 Sessions

ViaNews Editorial Team

September 25, 2023

Copper Futures Over 2% Down In The Last 5 Sessions

(VIANEWS) - Copper (HG) has been up by 2.37% for the last 5 sessions. At 05:50 EST on Monday, 25 September, Copper (HG) is $3.66.

Volume

Today's last reported volume for Copper is 18090, 99.99% below its average volume of 12007044966.15.

Volatility

Copper's last week, last month's, and last quarter's current intraday variation average was a negative 0.01%, a positive 0.70%, and a positive 1.01%, respectively.

Copper's highest amplitude of average volatility was 0.70% (last week), 0.92% (last month), and 1.01% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Copper's commodity is considered to be overbought (>=80).

News about

  • WTI crude oil: weekly forecast 24th September - 30th September - 24 September 2023. According to DailyForex on Sunday, 24 September, "Previous lows last week saw WTI briefly go below 89.000 on Wednesday, and the lowest mark for the week occur on Thursday as Crude Oil traded near the 88.130 ratio for a short time.", "Yes, WTI Crude Oil did traverse below its highs as it went into the weekend, but price remained durable as short-term support near 89.000 seemed to spark renewed buying when it was briefly penetrated a few hours before the commodity market closed. "
  • According to DailyForex on Sunday, 24 September, "S GDP numbers are strong and the costs for WTI Crude Oil remain near or above 90.000 USD per barrel.GBP/USD Weekly Outlook:"

More news about Copper (HG).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com